208 related articles for article (PubMed ID: 31256036)
1. Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol.
Ziegler AG; Achenbach P; Berner R; Casteels K; Danne T; Gündert M; Hasford J; Hoffmann VS; Kordonouri O; Lange K; Elding Larsson H; Lundgren M; Snape MD; Szypowska A; Todd JA; Bonifacio E;
BMJ Open; 2019 Jun; 9(6):e028578. PubMed ID: 31256036
[TBL] [Abstract][Full Text] [Related]
2. Supplementation with
Ziegler AG; Arnolds S; Kölln A; Achenbach P; Berner R; Bonifacio E; Casteels K; Elding Larsson H; Gündert M; Hasford J; Kordonouri O; Lundgren M; Oltarzewski M; Pekalski ML; Pfirrmann M; Snape MD; Szypowska A; Todd JA;
BMJ Open; 2021 Nov; 11(11):e052449. PubMed ID: 34753762
[TBL] [Abstract][Full Text] [Related]
3. Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials-GPPAD-02 study design and first results.
Winkler C; Haupt F; Heigermoser M; Zapardiel-Gonzalo J; Ohli J; Faure T; Kalideri E; Hommel A; Delivani P; Berner R; Kordonouri O; Roloff F; von dem Berge T; Lange K; Oltarzewski M; Glab R; Szypowska A; Snape MD; Vatish M; Todd JA; Larsson HE; Ramelius A; Kördel JÅ; Casteels K; Paulus J; Ziegler AG; Bonifacio E;
Pediatr Diabetes; 2019 Sep; 20(6):720-727. PubMed ID: 31192505
[TBL] [Abstract][Full Text] [Related]
4. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial.
Bonifacio E; Ziegler AG; Klingensmith G; Schober E; Bingley PJ; Rottenkolber M; Theil A; Eugster A; Puff R; Peplow C; Buettner F; Lange K; Hasford J; Achenbach P;
JAMA; 2015 Apr; 313(15):1541-9. PubMed ID: 25898052
[TBL] [Abstract][Full Text] [Related]
5. Primary islet autoantibody at initial seroconversion and autoantibodies at diagnosis of type 1 diabetes as markers of disease heterogeneity.
Ilonen J; Lempainen J; Hammais A; Laine AP; Härkönen T; Toppari J; Veijola R; Knip M;
Pediatr Diabetes; 2018 Mar; 19(2):284-292. PubMed ID: 28597949
[TBL] [Abstract][Full Text] [Related]
6. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.
Näntö-Salonen K; Kupila A; Simell S; Siljander H; Salonsaari T; Hekkala A; Korhonen S; Erkkola R; Sipilä JI; Haavisto L; Siltala M; Tuominen J; Hakalax J; Hyöty H; Ilonen J; Veijola R; Simell T; Knip M; Simell O
Lancet; 2008 Nov; 372(9651):1746-55. PubMed ID: 18814906
[TBL] [Abstract][Full Text] [Related]
7. Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial.
Assfalg R; Knoop J; Hoffman KL; Pfirrmann M; Zapardiel-Gonzalo JM; Hofelich A; Eugster A; Weigelt M; Matzke C; Reinhardt J; Fuchs Y; Bunk M; Weiss A; Hippich M; Halfter K; Hauck SM; Hasford J; Petrosino JF; Achenbach P; Bonifacio E; Ziegler AG
Diabetologia; 2021 May; 64(5):1079-1092. PubMed ID: 33515070
[TBL] [Abstract][Full Text] [Related]
8. Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes.
Giannopoulou EZ; Winkler C; Chmiel R; Matzke C; Scholz M; Beyerlein A; Achenbach P; Bonifacio E; Ziegler AG
Diabetologia; 2015 Oct; 58(10):2317-23. PubMed ID: 26138334
[TBL] [Abstract][Full Text] [Related]
9. Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population.
Kimpimäki T; Kulmala P; Savola K; Kupila A; Korhonen S; Simell T; Ilonen J; Simell O; Knip M
J Clin Endocrinol Metab; 2002 Oct; 87(10):4572-9. PubMed ID: 12364437
[TBL] [Abstract][Full Text] [Related]
10. Negativation of type 1 diabetes-associated autoantibodies to glutamic acid decarboxylase and insulin in children treated with oral calcitriol.
Papadimitriou DT; Marakaki C; Fretzayas A; Nicolaidou P; Papadimitriou A
J Diabetes; 2013 Sep; 5(3):344-8. PubMed ID: 23302101
[TBL] [Abstract][Full Text] [Related]
11. Disease-associated autoantibodies and HLA-DQB1 genotypes in children with newly diagnosed insulin-dependent diabetes mellitus (IDDM). The Childhood Diabetes in Finland Study Group.
Sabbah E; Savola K; Kulmala P; Reijonen H; Veijola R; Vähäsalo P; Karjalainen J; Ilonen J; Akerblom HK; Knip M
Clin Exp Immunol; 1999 Apr; 116(1):78-83. PubMed ID: 10209508
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial.
Vehik K; Cuthbertson D; Ruhlig H; Schatz DA; Peakman M; Krischer JP;
Diabetes Care; 2011 Jul; 34(7):1585-90. PubMed ID: 21610124
[TBL] [Abstract][Full Text] [Related]
13. Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol.
Ludvigsson J; Eriksson L; Nowak C; Teixeira PF; Widman M; Lindqvist A; Casas R; Lind M; Hannelius U
BMJ Open; 2022 Oct; 12(10):e061776. PubMed ID: 36316084
[TBL] [Abstract][Full Text] [Related]
14. Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.
; Krischer JP; Schatz DA; Bundy B; Skyler JS; Greenbaum CJ
JAMA; 2017 Nov; 318(19):1891-1902. PubMed ID: 29164254
[TBL] [Abstract][Full Text] [Related]
15. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
Skyler JS; Krischer JP; Wolfsdorf J; Cowie C; Palmer JP; Greenbaum C; Cuthbertson D; Rafkin-Mervis LE; Chase HP; Leschek E
Diabetes Care; 2005 May; 28(5):1068-76. PubMed ID: 15855569
[TBL] [Abstract][Full Text] [Related]
16. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes In Finland Study Group.
Sabbah E; Savola K; Kulmala P; Veijola R; Vähäsalo P; Karjalainen J; Akerblom HK; Knip M
J Clin Endocrinol Metab; 1999 May; 84(5):1534-9. PubMed ID: 10323375
[TBL] [Abstract][Full Text] [Related]
17. IA-2 autoantibodies predict impending type I diabetes in siblings of patients.
Decochez K; De Leeuw IH; Keymeulen B; Mathieu C; Rottiers R; Weets I; Vandemeulebroucke E; Truyen I; Kaufman L; Schuit FC; Pipeleers DG; Gorus FK;
Diabetologia; 2002 Dec; 45(12):1658-66. PubMed ID: 12488955
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility.
Pöllänen PM; Lempainen J; Laine AP; Toppari J; Veijola R; Vähäsalo P; Ilonen J; Siljander H; Knip M
Diabetologia; 2017 Jul; 60(7):1284-1293. PubMed ID: 28364254
[TBL] [Abstract][Full Text] [Related]
19. Disease-associated autoantibodies as surrogate markers of type 1 diabetes in young children at increased genetic risk. Childhood Diabetes in Finland Study Group.
Kimpimäki T; Kulmala P; Savola K; Vähäsalo P; Reijonen H; Ilonen J; Akerblom HK; Knip M
J Clin Endocrinol Metab; 2000 Mar; 85(3):1126-32. PubMed ID: 10720050
[TBL] [Abstract][Full Text] [Related]
20. Age at Seroconversion, HLA Genotype, and Specificity of Autoantibodies in Progression of Islet Autoimmunity in Childhood.
Bauer W; Veijola R; Lempainen J; Kiviniemi M; Härkönen T; Toppari J; Knip M; Gyenesei A; Ilonen J
J Clin Endocrinol Metab; 2019 Oct; 104(10):4521-4530. PubMed ID: 31120497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
